GigaGen isn't just making antibodies—it's capturing entire immune repertoires as functional libraries. In a field crowded with incremental improvements, they're taking a radical, single-cell approach to drug discovery that could rewrite the playbook for autoimmune and oncology treatments.

"They're not discovering antibodies—they're recreating complete immune repertoires as functional libraries."

The tech stack tells a story of modern biotech pragmatism: jQuery and Bootstrap for rapid prototyping, Tailwind CSS for clean design, Lottie for engaging animations, and Google Analytics for tracking the right metrics. No bloated frameworks—just tools that get the job done. The 33% organic search traffic suggests they're not gaming the system; they're building something worth searching for.

• Single-cell technology captures complete immune repertoires, not just individual antibodies
• Functional antibody libraries enable faster, more comprehensive drug discovery
• Deep leadership bench from Stanford, biotech giants, and academic medical centers
• Low public footprint with high direct traffic signals strong network effects